| Assessment Status | Awaiting response from Applicant |
| HTA ID | 24052 |
| Drug | Lecanemab |
| Brand | Leqembi® |
| Indication | Lecanemab (Leqembi®) is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early Alzheimer’s disease) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology. |
| Assessment Process | |
| Rapid review commissioned | 19/12/2024 |
| Rapid review completed | 28/01/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lecanemab compared with the current standard of care. |
| Full HTA commissioned by the HSE | 29/05/2025 |
| Pre-submission consultation with Applicant | 02/07/2025 |
| Full submission received from Applicant | 13/01/2026 |
| Preliminary review sent to Applicant | 10/04/2026 |
The assessment was paused on 11 May 2026 at the request of the Applicant.